CCND1 Recombinant Monoclonal Antibody

Code CSB-RA616025A0HU
Size US$210
Order now
  • Western Blot
    Positive WB detected in: NIH/3T3 whole cell lysate, SH-SY5Y whole cell lysate, U-87 whole cell lysate
    All lanes: Cyclin D1 antibody at 1:1000
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 34 kDa
    Observed band size: 34 kDa
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
G1/S-specific cyclin-D1 (B-cell lymphoma 1 protein) (BCL-1) (BCL-1 oncogene) (PRAD1 oncogene), CCND1, BCL1 PRAD1
Species Reactivity
Human, Mouse
A synthesized peptide derived from human Cyclin D1
Immunogen Species
Homo sapiens (Human)
Rabbit IgG
Clone No.
Purification Method
It differs from different batches. Please contact us to confirm it.
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
Troubleshooting and FAQs
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

The process of producing the CCND1 recombinant monoclonal antibody is intricate and multi-step. Initially, the CCND1 monoclonal antibody is collected and its genetic sequence is analyzed. A vector carrying the CCND1 monoclonal antibody gene is then constructed and incorporated into a host cell line for culturing. The CCND1 monoclonal antibody is generated using a synthetic peptide sourced from human CCND1 as an immunogen. Finally, the CCND1 recombinant monoclonal antibody is purified via affinity chromatography to ensure high purity. The antibody's specificity is then verified using ELISA and WB assays, which examine its ability to accurately identify CCND1. It detects human and mouse CCND1 proteins.

CCND1 protein is a regulatory protein that plays a critical role in cell cycle progression and cell differentiation. In response to extracellular signals, CCND1 is synthesized and binds to CDK4 or CDK6 to form an active complex that phosphorylates and inactivates the retinoblastoma protein (RB), leading to the release of E2F transcription factors thus promoting the expression of genes required for DNA replication and cell cycle progression. CCND1 promotes the differentiation of various cell types, including osteoblasts, adipocytes, and neurons, by regulating the activity of Runx2, PPARgamma, and CREB, respectively. Dysregulation of CCND1 can contribute to the development and progression of cancer.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.
Gene References into Functions
  1. LINC01296 is an oncogenic lncRNA in osteosarcoma. The proliferation, invasion and migration of osteosarcoma cells could be effectively retarded by inhibition of LINC01296. The cancerpromoting effect of LINC01296 on osteosarcoma was determined by cyclin D1. PMID: 30226542
  2. autophagic degradation machinery and cyclin D1 linked to hepatocellular carcinoma tumorigenesis PMID: 29328502
  3. FOXD2-AS1 could promote the growth of chondrocytes by targeting miR-206/CCND1 axis. PMID: 30119190
  4. CCND1 , C-MYC , and FGFR1 amplifications were observed in 34.28%, 28.57%, and 17.14% of the 35 samples (invasive ductal breast carcinoma). PMID: 30119151
  5. High CCND1 expression is associated with lung adenocarcinoma. PMID: 30066899
  6. Down-regulation of Apaf-1 protein and the overexpression of Cyclin D1 and AQP-5 proteins possibly contribute to an aggressive serous ovarian carcinoma with a high risk of recurrence and poor response to the first-line chemotherapy. PMID: 30072015
  7. Results provide evidence that Cyclin D1 is a mediator for WDR5-induced proliferation and cell cycle change in gastric neoplasm. PMID: 29125890
  8. CNV analysis disclosed that plasma CCND1/CDKN2A ratio is correlated with EBV DNA load in NPC patients' plasma and could serve as a screening test to select potential CDK4/6 inhibitor treatment candidates. Based on our NPC PDX model and RNA sequencing, Palbociclib, a cyclin-dependent kinase inhibitor, proved to have anti-tumor effects by inducing G1 arrest. PMID: 30236142
  9. Cyclin D1b markedly amplified integrin alphavbeta3 expression, which was further up-regulated under lipopolysaccharide stimulation. PMID: 30074214
  10. This meta-analysis suggested that CCND1 rs9344 polymorphism might be associated with the risk of HCC among Caucasians. PMID: 29970717
  11. Results show that CCND1 expression is regulated by LET7A which directly targets its 3'UTR in A549 lung cancer cells. PMID: 30201337
  12. Authors found that the phenotypic alterations by miR-365 were partially due to downregulation of CCND1 and BCL2 oncogenes. PMID: 29858490
  13. USP22 and CCND1 levels correlate in patient lung and colorectal cancer samples and our preclinical studies indicate that targeting USP22 in combination with CDK inhibitors may offer an approach for treating cancer patients whose tumors exhibit elevated CCND1. PMID: 30224477
  14. miR449a5p may control squamous cell carcinoma proliferation through the negative regulation of cyclin D1 expression. PMID: 29845226
  15. Findings demonstrated that Cyclin D1 is overexpressed in hepatocellular carcinoma cells (HCC) and that its silencing can suppress cell proliferation and promote cell apoptosis of HCC. PMID: 28885717
  16. uc.338 could promote proliferation and cell cycle G1/S transition, and might target p21 downregulation and cyclin D1 upregulation. PMID: 29901203
  17. overexpressed PKM2 led to increased CCND1 and decreased CDKN1A expression, whereas underexpressed PKM2 led to decreased CCND1 and increased CDKN1A expression in ovarian cancer cells. PMID: 29752805
  18. CCND1 G870A polymorphism may increase the risk of lung cancer in smokers from North India, and it may be associated with the overall survival of small-cell lung cancer patients PMID: 30086699
  19. these results define a tumor-supportive role for CDCA3. PMID: 29627567
  20. High CCND1 expression is associated with breast cancer. PMID: 29047106
  21. The novel EGR1-CCND1 axis contributes to the G1 phase arrest and cell proliferation in glioma PMID: 29246166
  22. the focal adhesion component paxillin is a cytoplasmic substrate of Ccnd1.Cdk4. PMID: 27181366
  23. in oral tumor cells, overexpression of cyclin D1 occurs through the activation of STAT3 and the deregulation of degradation pathway of cyclin D1 which may favors maintaining its accumulated level in cells. It also demonstrated that cyclin D1 expression can be controlled by targeting the STAT3 with its siRNA. PMID: 29516928
  24. more than 50 cyclin D1-positive cells per high-power field were detected within the proliferation centres PMID: 29254788
  25. Downregulation of miR-138 increases the gene and protein expression of its potential target CCND1 in OLP mucosa which might have a pivotal role in the disease pathogenesis. PMID: 28275859
  26. A possible contribution of cyclin D1 and hnRNP-K expression in the initiation and progression of urinary bladder carcinoma. PMID: 29480994
  27. Un-methyaltion at -56 and -54 bp CpG in the CCND1 promoter serves as a predictor for invasive progression in arsenic-induced Bowen's disease patients. PMID: 29103775
  28. PSAT1, which is overexpressed in ER-negative breast cancers, is activated by ATF4 and promotes cell cycle progression via regulation of the GSK3beta/beta-catenin/cyclin D1 pathway. PMID: 29216929
  29. Positivity of p53 and cyclin D1 was not found to be predictive of survival in patients with esophageal SCC which might be due to the small sample size of the present survey. PMID: 27975182
  30. Studied effects of Taxillus yadoriki and Neolitsea sericea extracts on cell proliferation of cancer cells through cyclin D1 proteasomal degradation. PMID: 29925351
  31. Findings indicate the substrate specificity of the F-box protein FBXO31 and the mechanism of FBXO31-regulated cyclin D1 protein turnover. PMID: 29279382
  32. The authors report a previously unknown long noncoding RNA which, together with CNBP, is involved in the fine-tuned regulation of CCND1 mRNA stability, without which CCND1 exhibits, at most, partial expression. PMID: 29199958
  33. According to immunohistochemistry and immunoblot analysis, the expression levels of cyclin D1, cyclin E, pRb, and Ki67 in psoriasis lesions decreased after treatment and were similar with those in the normal group PMID: 29115643
  34. Further study revealed AP000439.3 can regulate expression of CCND1 through enhancing estrogen receptor induction of CCND1. This finding revealed lncRNAs may serve as important effectors of ER in regulation of gene expression and cell phenotype in breast cancer PMID: 29048636
  35. miR-720 acted as a tumour suppressor in pancreatic cancer by directly targeting CCND1. PMID: 28990111
  36. Results identified NKX2-1-binding motifs in the cyclin D1 promoter and indicate that NKX2-1 directly and positively regulates transcription of cyclin D1 in lung adenocarcinoma. PMID: 28634225
  37. Results suggest that dysregulation and activation of the cell cycle proteins CDK4/CDK6-CCND1-phospho-RB1 axis is associated with higher proliferative index in neuroendocrine tumors (NETs). PMID: 28991877
  38. Results indicated that miR-193a-3p suppressed gastric growth and motility, at least partly, by directly targeting cyclin D1 (CCND1) and ETS proto-oncogene 1 (ETS1) expression. PMID: 29848678
  39. Greater frequency of cyclin D1 expression was revealed in normal endometrial tissues in comparison with carcinomas. The distribution pattern of cyclin D1 immunoexpression suggests poor prognoses in endometrial carcinoma patients. PMID: 28965628
  40. High Expression of CCND1 is associated with liver cancer. PMID: 28415588
  41. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas. PMID: 29489901
  42. These findings indicate that miRNA494 and its target cyclin D1 may be a crucial axis for Nerve growth factor in regulating the proliferation of human corneal epithelial cell. PMID: 28765880
  43. INSR rs1051690 SNP is associated with increased risk of gastric cancer, while polymorphisms in IL12B, CCND1 and IL10 genes are not linked with the presence of gastric cancer PMID: 28596683
  44. Authors showed that CCND1 is a direct target of miR-93, and the dysregulation of the miR-93/CCND1 signaling pathway is responsible for the development of ventricular remodeling. PMID: 28817550
  45. PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation PMID: 29160310
  46. We conclude that EMSY and CCND1 work in collaboration and contribute to the pathogenesis of lung cancer. PMID: 28824300
  47. Transfection of cells with ClC-3 siRNA decreased the expression of cyclin D1, cyclin dependent kinase 4 and 6, and increased the expression of cyclin dependent kinase inhibitors (CDKIs), p21 and p27. Pretreatments of cells with p21 and p27 siRNAs depleted the inhibitory effects of ClC-3 siRNA on the expression of CDK4 and CDK6, but not on that of cyclin D1 PMID: 27451945
  48. HPV infection was significantly associated with amplification of both EGFR (76.5%) and cyclin D1 (73.0%). PMID: 28741068
  49. our data demonstrated for the first time that inhibition of RAD51 suppressed the cervical cancer cell proliferation and the growth of cervical cancer xenografts by attenuating cell cycle transition, which could be a functional link between RAD51 and cyclin D1 and p21 PMID: 28627709
  50. REVIEW: addresses the implication of SOX11 overexpression and frequent genetic lesions, cooperating with cyclin D1 underlying the pathogenesis of mantle cell lymphoma PMID: 28466437

Show More

Hide All

Involvement in disease
Multiple myeloma (MM)
Subcellular Location
Nucleus. Cytoplasm. Nucleus membrane.
Protein Families
Cyclin family, Cyclin D subfamily
Database Links

HGNC: 1582

OMIM: 168461

KEGG: hsa:595

STRING: 9606.ENSP00000227507

UniGene: Hs.523852

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To